Update on potential drugs for the treatment of diabetic kidney disease

Clinical Therapeutics
Brian SheplerStephanie Szewciw

Abstract

Although controlling hyperglycemia and proteinuria is currently the main focus of diabetic kidney disease management, some existing drugs and other new compounds are being evaluated for their ability to interrupt the disease process. Specifically, drugs that interfere with the formation and action of advanced glycation end products and reduce or inhibit fibrosis of the glomerular structures in the presence of hyperglycemia are just 2 examples. The aim is to provide an in-depth review of drugs currently being investigated to treat diabetic kidney disease (DKD) through novel mechanisms of action that interrupt the pathologic process. A literature search was performed of the search engines PubMed (www.pubmed.gov) and ClinicalTrials.gov (www.clinicaltrials.gov), initially using the broad search terms diabetic nephropathy, diabetic kidney disease, and advanced glycation end products. Limits were set to include only English-language articles and studies performed in human subjects from January 2000. Previous review articles on this subject captured through the initial search also served as a basis for identifying drugs that had been under evaluation. Once a list of drugs and compounds was established, each agent was used as an indepe...Continue Reading

References

Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Mar 31, 2000·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·S FavaP J Watkins
Nov 10, 2000·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·T MiyazakiT Niwa
Mar 29, 2001·Diabetologia·R SinghL Beilin
Mar 22, 2002·Journal of Internal Medicine·H Vlassara, M R Palace
Jun 1, 2002·Journal of the American Society of Nephrology : JASN·Giovanni GambaroGaetano Crepaldi
Nov 22, 2002·Journal of the American Society of Nephrology : JASN·Shuei-Liong LinTun-Jun Tsai
Mar 3, 2004·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Yung-Ming ChenTun-Jun Tsai
May 25, 2004·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Tsutomu SanakaShozo Koshikawa
Apr 19, 2005·Expert Opinion on Investigational Drugs·Kei FukamiJosephine M Forbes
Aug 9, 2006·Human Molecular Genetics·Chang-Hsun HsiehEllson Y Chen
Feb 6, 2007·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·UNKNOWN KDOQI
Aug 21, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Katherine R TuttleUNKNOWN PKC-DRS, PKC-DMES, and PKC-DRS 2 Study Groups
Dec 20, 2007·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Hiddo Lambers HeerspinkUNKNOWN Collaborative Study Group
Jun 6, 2008·The New England Journal of Medicine·Hans-Henrik ParvingUNKNOWN AVOID Study Investigators
Oct 25, 2008·Cardiovascular Drugs and Therapy·Nehal N MehtaMuredach P Reilly
Jan 16, 2009·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Hans-Henrik ParvingMarc A Pfeffer
May 1, 2009·Nature Reviews. Drug Discovery·Nigel A CalcuttAnn Marie Schmidt
May 13, 2009·Current Opinion in Nephrology and Hypertension·Basil O BurneyGeorge L Bakris
Jul 7, 2009·Journal of the American Society of Nephrology : JASN·Satish P RamachandraRaoKumar Sharma
Jul 25, 2009·Journal of Clinical Pharmacology·Patricia N SidhartaJasper Dingemanse
Feb 9, 2010·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Faruk Turgut, Warren Kline Bolton
Mar 10, 2010·Seminars in Dialysis·Eli A Friedman
Mar 17, 2010·Hypertension·Liffert VogtUNKNOWN PROLONG (PROteinuria Lowering with urOteNsin receptor antaGonists) Study Group
Apr 28, 2010·Nature Reviews. Nephrology·Vivette D'Agati, Ann Marie Schmidt
Apr 29, 2010·JAMA : the Journal of the American Medical Association·Andrew A HouseJ David Spence
May 5, 2010·Nature Reviews. Nephrology·Piero RuggenentiGiuseppe Remuzzi
May 5, 2010·Nature Reviews. Nephrology·Anne-Emilie Declèves, Kumar Sharma
May 7, 2010·The Journal of Clinical Endocrinology and Metabolism·Joshua A BeckmanMark A Creager
Jun 5, 2010·Clinical Journal of the American Society of Nephrology : CJASN·Sharon G AdlerK Lea Sewell
Aug 17, 2010·Diabetes Research and Clinical Practice·Yasuaki HayashinoUNKNOWN CAP-KD study group
Oct 6, 2010·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Young Sun KangDae Ryong Cha
Dec 15, 2010·Journal of Diabetes and Its Complications·Juan F Navarro-GonzálezJavier García
May 4, 2011·Nature Reviews. Nephrology·Juan F Navarro-GonzálezJavier García-Pérez
Jun 28, 2011·The New England Journal of Medicine·Pablo E PergolaUNKNOWN BEAM Study Investigators
Aug 13, 2011·Nature Reviews. Drug Discovery·Luca RicheldiPeter Kirkpatrick
Aug 30, 2011·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Edmund J LewisUNKNOWN Collaborative Study Group

❮ Previous
Next ❯

Citations

Nov 13, 2014·Journal of Diabetes Research·Laura A MaileDavid Clemmons
Jan 28, 2014·Journal of Pharmaceutical and Biomedical Analysis·Mara ColzaniGiancarlo Aldini
Sep 18, 2014·Reproductive Sciences·Magdalena Pertynska-Marczewska, Zaher Merhi
Apr 12, 2014·Journal of the American Society of Nephrology : JASN·Olivia LenoirPierre-Louis Tharaux
Jul 31, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Junmin WangGuang Ji

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.